Thus, future studies using a combination of pharmacological and genetic approaches are needed to determine the role of each specific HDAC isoform at various times during MS, and how the disease may benefit from approaches that include inhibitors for both HDAC11 and HDAC6 isoforms. Here, HDAC6 is linked to myeloid sarcoma.